ОСНОВНЫЕ НАПРАВЛЕНИЯ МОДИФИКАЦИИ ПОВЕРХНОСТИ МЕТАЛЛИЧЕСКИХ ЭНДОВАСКУЛЯРНЫХ СТЕНТОВ В РЕШЕНИИ ПРОБЛЕМЫ РЕСТЕНОЗОВ (ОБЗОР 1 ЧАСТЬ

Рестенозы металлических стентов, возникающие после имплантации, остаются нерешенной проблемой и  существенно ограничивают их терапевтическую эффективность. В обзоре освещены наиболее перспективные с точки зрения физиологии и клеточной биологии варианты модификации металлических поверхностей, представлены преимущества и недостатки каждого из методов. В первую часть обзора включены направления, касающиеся разработки стентов с антитромботическим и антипролиферативным покрытием, так же представлены наиболее значимые и интересные исследования, направленные на формирование на поверхности стентов эндотелиального слоя in vitro.

1. Сердечно-сосудистые заболевания. Информационный бюллетень. Январь 2015; 317. Режим доступа: http://www.who.int/mediacentre/factsheets/fs317/ru/. Serdechno-sosudistye zabolevanija. Informacionnyj bjulleten’. Janvar’ 2015; 317. Аvailable from: http://www.who.int/mediacentre/factsheets/fs317/ru/.

2. Farhatnia Y., Tan A., Motiwala A., Cousins B.G., Seifalian A.M. Evolution of covered stents in the contemporary era: clinical application, materials and manufacturing strategies using nanotechnology. Biotechnol Adv. 2013; 31(5): 524-542.

3. Kabir A.M., Selvarajah A., Seifalian A.M. How safe and how good are drug-eluting stents? Future Cardiol. 2011; 7(2): 251-270. doi:10.2217/fca.11.1.

4. Mani G., Feldman M.D., Patel D., Agrawal C.M. Coronary stents: A materials perspective. Biomaterials 2007; 28(9):1689-1710.

5. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 2006; 39: 484–489.

6. Steffel J., Eberli F.R., Luscher T.F., Tanner F.C. Drug-eluting stents - what should be improved? Ann Med. 2008; 40(4): 242-52.

7. Mani G., Chandrasekar B., Feldman M.D., Patel D., Agrawal C.M. Interaction of endothelial cells with self-assembed monolayers for potential use in drug-eluting coronary stents. J Biomed Mater Res B Appl Biomater. 2009; 90(2): 789-801. doi:10.1002/jbm.b.31348.

8. Stoebner S. E., Mani G. Effect of processing methods on drug release profiles of antirestenotic self-assembled monolayers. Appl. Surf. Sci. 2012; 258(12): 5061−5072. doi:10.1016/j.apsusc.2012.01.106.

9. Mani G., Torres N., Oh S. Paclitaxel delivery from cobaltchromium alloy surfaces using self-assembled monolayers. Biointerphases. 2011; 6(2): 33-42. doi: 10.1116/1.3575530.

10. Garg H.G., Mrabat H., Yu L., Freeman C., Li B., Zhang F. et al. Effect of carboxyl-reduced heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells. Carbohydr Res. 2010; 345(9): 1084-1087. doi:10.1016/j.carres.2010.03.026.

11. Moreno R., Fernandez C., Sanchez-Recalde A., Calvo L., Galeote G., Sanchez-Aquino R. et al. Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation. Br J Clin Pharmacol. 2007; 64(1): 110–112. doi:10.1111/j.1365-2125.2006.02840.x

12. Wessely R., Blaich B., Belaiba R.S., Merl S., Görlach A., Kastrati A. et al. Comparative characterization of cellular and molecular antirestenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb. Haemost. 2007; 97(6): 1003-1012.

13. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgio G.M., Stankovic G. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. AMA 2005; 293(17): 2126–2130.

14. Strang A.C., Knetsch M.L.W., Koole L.H., de Winter R.J., van der Wal A.C., de Vries C.J.M. et al. Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon- Injury Model. PLoS ONE 2015; 10(3): e0122836. doi:10.1371/journal.pone.0122836.

15. Billinger M., Buddeberg F., Hubbell J.A., Elbert D.L., Schaffner T., Mettler D. et al. Polymer stent coating for prevention of neointimal hyperplasia. J Invasive Cardiol. 2006; 18(9): 423-427.

16. Kim J.H., Shin J.H., Shin D.H., Moon M.W., Park K., Kim T.H. et al. Comparison of diamondlike carbon-coated nitinol stents with or without polyethylene glycol grafting and uncoated nitinol stents in a canine iliac artery model. Br J Radiol. 2011; 84(999): 210-215. doi:10.1259/bjr/21667521.

17. Reifart N., Morice M.C., Silber S., Benit E., Hauptmann K.E., de Sousa E. et al. The NUGGET study: NIR ultra gold-gilded equivalency trial. Catheter. Cardiovasc. Interv. 2004; 62(1): 18-25. doi:10.1002/ccd.20026.

18. Antoniucci D., Valenti R., Migliorini A., Moschi G., Trapani M., Bolognese L. et al. Clinical and angiographic outcomes following elective implantation of the Carbostent in patients at high risk of restenosis and target vessel failure. Catheter. Cardiovasc. Interv. 2001; 54: 420- 426.

19. Lewis A.L. Phosphorylcholine-based polymers and their use in the prevention of biofouling. Colloids Surf B Biointerfaces. 2000; 18(3-4): 261-275.

20. Whelan D.M., van der Giessen W.J., Krabbendam S.C., van Vliet E.A., Verdouw P.D., Serruys P.W. at al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart. 2000; 83(3): 338-345.

21. Hardhammar P., Beusekom H.V., Emanuelsson H., Hofma S., Albertsson P., Verdouw P. et al. Reduction in thrombotic events with heparincoated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93(3): 423-430.

22. Breckwoldt W., Belkin M., Gould K., Allen M., Connolly R., Termin P. Modification of the thrombogenicity of a self-expanding vascularstent. J Invest Surg. 1991; 4(3): 269-278.

23. Grode G., Anderson S., Grotta H., Falb R. Nonthrombogenic materials via a simple coating process. Trans Am Soc Artif Intern Organs 1969; 15: 1-6.

24. Tanzawa H., Mori Y., Harumiya N., Miyama H., Hori M., Ohshima N. et al. Preparation and evaluation of a new athrombogenic heparinized hydrophilic polymer for use in cardiovascular system. Trans Am Soc Artif Intern Organs 1973; 19: 188-194.

25. Larm O., Larssom R., Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11(2-3): 161-173.

26. Goosen M., Sefton M. Properties of a heparin-poly(vinyl alcohol) hydrogel coating. J Biomed Mater Res 1983; 17(2): 359-373.

27. Mazid M.A., Scott E., Li N-H. New biocompatible polyurethane-type copolymer with low molecular weight heparin. Clin Mater 1991; 8(1-2):.71-80.

28. Wohrle J., Al-Khayer E., Grotzinger U., Schindler C., Kochs M., Hombach V. et al. Comparison of the heparin coated vs. the uncoated Jostent–No influence on restenosis or clinical outcome. Eur. Heart J. 2001; 22: 1808-1816.

29. Windecker S., Mayer I., De Pasquale G., Maier W., Dirsch O., De Groot P., et al. Working Group on Novel Surface Coating of Biomedical Devices (SCOL). Stent coating with titaniumnitride- oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928- 933.

30. Ries T., Buhk J.H., Kucinski T., Goebell E., Grzyska U., Zeumer H. et al. Intravenous administration of acetylsalicylic acid during endovascular treatment of cerebral aneurysms reduces the rate of thromboembolic events. Stroke 2006; 37 (7): 1816-1821.

31. Krajewskia S., Neumanna B., Kurza J., Perlea N., Avci-Adalia M., Cattaneob G. et al. Preclinical Evaluation of the Thrombogenicity and Endothelialization of Bare Metal and Surface-Coated Neurovascular Stents. AJNR Am J Neuroradiol. 2015 ; 36(1): 133-9. doi:10.3174/ajnr.A4109.

32. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R. et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001; 104 (10): 1188-1193.

33. Windecker S., Simon R., Lins M., Klauss V., Eberli F.R., Roffi M. et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation. 2005; 111(20): 2617- 2622.

34. Ormiston J.A., Serruys P.W.S. Bioabsorbable Coronary Stents. Circ Cardiovasc Intervent. 2009; 2: 255-260.

35. Mattesini A., Secco G.G., Dall’Ara G., Ghione M., Rama-Merchan J.C., Lupi A. et al. ABSORB Biodegradable Stents Versus Second- Generation Metal Stents. JACC: Сardiovascular interventions 2014; 7(7): 741-750.

36. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S. et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000; 102(4): 399-404.

37. Erbel R., di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F.R. et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non- randomised multicentre trial. Lancet. 2007; 369(9576): 1869- 1875. doi:10.1016/S0140-6736(07)60853-8.

38. Serruys P.W., Ong A.T., Piek J.J., Neumann F.J., van der Giessen W.J., Wiemer M. et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention 2005; 1(1): 58-65.

39. Jeewandara T.M., Wise S.G., Ng M.K.C. Biocompatibility of Coronary Stents. Review. Materials 2014, 7, 769-786; doi:10.3390/ma7020769.

40. Zhu W., Tian Y., Zhou L. F., Wang Y., Song D., Mao Y. and Yang G.Y. Development of a novel endothelial cell-seeded endovascular stent for intracranial aneurysm therapy. J Biomed Mater Res A. 2008; 85(3): 715-721.

41. Yang Y. G., Tang G., Yan J. L., Park B., Hoffman A., Tie G. et al. Cellular and Molecular Mechanism Regulating Blood Flow Recovery in Acute Versus Gradual Femoral Artery Occlusion Are Distinct in the Mouse. J. Vasc. Surg. 2008; 48: 1546- 1558.

42. Xia Y., Prawirasatya M., Heng B.C., Boey F. and Venkatraman S.S. Seeding density matters: extensive intercellular contact masks the surface dependence of endothelial cell- biomaterial interactions. J Mater Sci Mater Med. 2011; 22(2): 389-96. doi:10.1007/s10856-010-4211-5.

43. Wu X., Zhao Y., Tang C., Yin T., Du R., Tian J., Huang J., Gregersen H., Wang G. Re- Endothelialization Study on Endovascular Stents Seeded by Endothelial Cells through Up- or Downregulation of VEGF. ACS Appl. Mater. Interfaces 2016; 8 (11): 7578-7589. doi: 10.1021/acsami.6b00152.

44. Allen J., Khan S., Serrano M. C., Ameer G. Characterization of porcine circulating progenitor cells: toward a functional endothelium. Tissue Eng Part A. 2008; 14(1): 183-194. doi:10.1089/ten.a.2007.0265.

45. Consigny P. Endothelial cell seeding on prosthetic surfaces. J Long Term Eff Med Implants 2000; 10(1–2): 79–95.

46. Luan Y., Liu X.C., Zhang G.W., Shi R.F., Zhao X.B., Zhao C.H. et al. Mid-term effect of stem cells combined with transmyocardial degradable stent on swine model of acute myocardial infarction. Coron Artery Dis. 2010; 21(4): 233-243. doi:10.1097/MCA.0b013e328338cc94.

47. Lim S.H., Cho S.W., Park J.C., Jeon O., Lim J.M., Kim S.S. et al. Tissue-engineered blood vessels with endothelial nitric oxide synthase activity. J Biomed Mater Res B Appl Biomater. 2008; 85(2): 537-546.

48. Gong Z., Niklason L.E. Small-diameter human vessel wall engineered from bone marrowderived mesenchymal stem cells ( hMSCs). FASEB J. 2008; 22(6): 1635-1648. doi: 10.1096/fj.07-087924.

49. Wu X., Wang G., Tang C., Zhang D., Li Z., Du D., Zhang Z. Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent. J Biomed Mater Res A. 2011; 98(3): 442-449. doi:10.1002/jbm.a.33133.

50. Keilhoff G., Stang F., Goihl A., Wolf G., Fansa H. Transdifferentiated mesenchymal stem cells as alternative therapy in supporting nerve regeneration and myelination. Cell Mol Neurobiol. 2006; 26(7-8): 1235-1252.

51. Kipshidze N., Dangas G., Tsapenko M., Moses J., Leon M.B., Kutryk M. et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004; 44(4): 733–739. doi:10.1016/j.jacc.2004.04.048.